Cross-sectional study into quality of life issues surrounding insulin pump use in type 1 diabetes

Practical Diabetes International

Volumn 25, Issue 5, 2008, Pages 194-200

  Barnard, Katharine D ^a   Skinner, T Chas ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

CSH; Health outcome; Health status; Insulin infusion; Insulin pump; QoL; Weil being

Indexed keywords

INSULIN;

AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; CONFOUNDING VARIABLE; CONTINUOUS INFUSION; CROSS-SECTIONAL STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; HYPOGLYCEMIA; HYPOGLYCEMIA FEAR SCALE; INSULIN DELIVERY SYSTEM RATING QUESTIONNAIRE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; PROBLEM AREAS IN DIABETES SCALE; QUALITY OF LIFE; QUESTIONNAIRE; SELF CARE; SEX DIFFERENCE; SOCIOECONOMICS; TREATMENT DURATION; UNITED KINGDOM; WORLD HEALTH ORGANIZATION QUALITY OF LIFE QUESTIONNAIRE;

EID: 54949103984     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.1248     Document Type: Article

References (29)

1. Bradley C, Speight J. Patient perceptions of diabetes and diabetes therapy: assessing QoL. Diabetes Metab Res Rev 2002; 18(Suppl 3): S64-S69.
2. Bode BW, Sabbah HT, Gross TM, et al. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 2002; 18(Suppl 1): S14-S20.
3. Rodrigues IAS, Reid HA, Ismail K, et al. Indications and efficacy of continuous subcutaneous insulin infusion (CSII) therapy in Type 1 diabetes mellitus: a clinical audit in a specialist service. Diabetic Med 2005; 22: 842-849.
4. Personal communication with Roche Diagnostics, manufacturers of insulin pump, 2005.
5. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003; 26: 1079-1087.
6. Chantelau E, Schiffers T, Schutze J, et al. Effect of patient-selected intensive insulin therapy on QoL. Patient Educ Couns 1997; 30: 167-173.
7. Barnard KD, Lloyd CE, Skinner TC. Systematic literature review into quality of life issues associated with insulin pump use in Type 1 diabetes. Diabetic Med 2007; 24: 607-617.
8. Linkeschova R, Raoul M, Bott U, et al. Less severe hypoglycaemia, better metabolic control and improved QoL in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabetic Med 2002; 19: 746-751.
9. Bruttomesso D, Pianta A, Crazzolara D, et al. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and QoL. Diabetic Med 2002; 19: 628-634.
10. Boland EA, Grey M, Oesterle A, et al. Continuous subcutaneous insulin infusion: a new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22: 1779-1784.
11. Hoogma RPLM, Spijker AJM, van Doorn-Scheele M, et al. Quality of life and metabolic control in patients with diabetes mellitus type I treated by continuous subcutaneous insulin infusion or multiple daily insulin injections. Neth J Med 2004; 62(10): 383-387.
12. Tsui E, Barnie A, Ross S, et al. Intensive Insulin Therapy with Insulin Lispro. A randomised trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care 2001; 24: 1722-1727.
13. Weintrob N, Benzaquen H, Galatzer A, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics 2003; 112: 559-564.
14. Hoogma RPLM, Hammond PJ, Gomis R, et al. on behalf of the 5 Nations Study Group. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and QoL: results of the 5-nations trial. Diabetic Med 2006; 23: 141-147.
15. Bartlett C, Doyal L, Ebrahim S, et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess 2005; 9(38).
16. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1995; 272: 619-626.
17. Speight J, Shaw JAM. Does one size really fit all? Only by considering individual preferences and priorities will the true impact of insulin pump therapy on QoL be determined. Diabetic Med 2007; 24: 693-695.
18. Barnard KD, Skinner TC. Qualitative study into quality of life issues surrounding insulin pump use in type 1 diabetes. Pract Diabetes Int 2007; 24: 143-148.
19. Skevington SM, Lotfy M, O'Connell K, and the WHOQOL Group. The World Health Organization's WHOQOL-BREF QoL assessment: Psychometric properties and the results of the international field trial. A Report from the WHOQOL Group. QoL Res 2004; 13(2): 299-310.
20. Akvardar Y, Akddede Bb, Özerdem A, et al. Assessment of quality of life with the WHOQOL-BREF in a group of Turkish psychiatric patients compared with diabetic and healthy subjects. Psychiatry Clin Neurosci 2006; 60(6): 693-699.
21. Peyrot M, Rubin R. Validity and Reliability of an Instrument for Assessing Health-Related QoL and Treatment Preferences. Diabetes Care 2005; 28: 53-58.
22. Cox DJ, Irvine A, Gonder-Frederick L, et al. Fear of hypoglycemia: Quantification, validation, and utilization. Diabetes Care 1987; 10: 617-621.
23. Evans JM, Newton RW, Ruta DA, et al. Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. BMJ 1999; 319(7202): 83-86.
24. Schütt M, Kern W, Krause U, et al; DPV Initiative. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria. Exp Clin Endocrinol Diabetes 2006; 114(7): 384-388.
25. Polonsky WH, Anderson BJ, Lohrer PA, et al. Assessment of diabetes-specific distress. Diabetes Care 1995; 18: 754-760.
26. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ 2002; 325: 746-749 [abridged version; full paper available at http://www.bmj.com].
27. King M, Nazareth I, Lampe F, et al. Conceptual Framework and Systematic Review of the Effects of Participants' and Professionals' Preferences in Randomised Controlled Trials. Health Technol Assess 2005; 9(35).
28. Brewin C, Bradley C. Patients' preferences and randomised clinical trials. BMJ 1989; 299: 313-315.
29. Bradley C. Importance of differentiating health status from quality of life. Lancet 2001; 357(9249): 7-8.